Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

FDA drug approval process, pharmaceutical regulatory compliance, food and drug administration certification, medical product approval concept, drug testing and approval | image credit: © Сергей Шиманович - © Сергей Шиманович - stock.adobe.com

October 5th, 2026

FDA Delays Novo Nordisk's Denecimig Over Facility Fixes

Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.

Group of Vaccine bottles. Medicine in ampoules. Glass vials for liquid samples in laboratory. | Image credit: © ronnarong - © ronnarong - stock.adobe.com

October 5th, 2026

Alvotech Wins FDA Nod for 2nd Simlandi Manufacturing Suite

Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.

October 2nd, 2026

Amino Acid Count Determines Retatrutide's Biologic or Drug Classification

LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.

FDA - US Food and Drug Administration | Image credit: © gguy - © gguy - stock.adobe.com

October 1st, 2026

FDA Warns Fresenius Kabi Over Sterile Injectable Contamination

Patients suffered pyrogenic reactions before Fresenius Kabi recalled 3 contaminated batches at its 430,000-sq-ft Melrose Park, Ill., biologics plant.

A disposable syringe is filled with a clear liquid and lies on a metal table. Disposable syringe with three glass vials of medicines. 3d render. | Image credit: © Alexandr - © Alexandr - stock.adobe.com

September 30th, 2026

Teva's Denosumab-Adet (Degevma) Approved as Xgeva Biosimilar

Denosumab-adet now covers all 3 Xgeva indications, widening lower-cost treatment access for cancer patients with bone complications.

Regenerative medicine and therapeutic stem cell therapy to regrow damaged cells as treatment for disease as multicellular organisms for cellular treatment of injury or arthritis illness due to aging | Image credit: © freshidea - © freshidea - stock.adobe.com

September 29th, 2026

iRegene's NouvSight001 Cleared for US and China RP Trials

NouvSight001 isn't limited to the RPE65-mutation subset current gene therapy treats, potentially reaching more of the 1.5 million with RP worldwide.

3D Rendering of Antibody Drug Conjugate Molecules - ADC - with cytotoxic payload | Image credit: © Alpha Tauri 3D - © Alpha Tauri 3D - stock.adobe.com

September 28th, 2026

Daiichi Sankyo, Merck Pull Ifinatamab Deruxtecan BLA in SCLC

Daiichi Sankyo and Merck pulled ifinatamab deruxtecan's FDA filing in small cell lung cancer after a 187-patient trial fell short.

Scientist Examining Medical Documents Near Ampoules and Pills | Image Credit: ©PixelPulse-stock.adobe.com

September 28th, 2026

IPEC’s EIP: A Standardized Communication Platform for Sharing Excipient Information as an Alternative to Questionnaires

IPEC’s EIP user guide streamlines information exchange and response times while increasing accuracy through standardization.